NVS Stock Recent News

NVS LATEST HEADLINES

NVS Stock News Image - zacks.com

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

zacks.com 2025 Jul 03
NVS Stock News Image - reuters.com

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.

reuters.com 2025 Jul 03
NVS Stock News Image - prnewswire.com

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1 EAST HANOVER, N.J. , July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

prnewswire.com 2025 Jul 03
NVS Stock News Image - globenewswire.com

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

globenewswire.com 2025 Jul 03
NVS Stock News Image - zacks.com

As Wall Street faces mixed moves in July, NVS, ALG, MT, BILI and STRL stand out as low-leverage stocks to weather volatility.

zacks.com 2025 Jul 02
NVS Stock News Image - zacks.com

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

zacks.com 2025 Jul 01
NVS Stock News Image - 247wallst.com

As you look at the stock markets around the world, it's always a balance of trying to decide when is the right time to buy.

247wallst.com 2025 Jun 29
NVS Stock News Image - youtube.com

The Investment Committee give you their top stocks to watch for the second half.

youtube.com 2025 Jun 26
NVS Stock News Image - globenewswire.com

ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target

globenewswire.com 2025 Jun 26
NVS Stock News Image - globenewswire.com

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

globenewswire.com 2025 Jun 25
10 of 50